BioXcel Therapeutics, Inc. — Form 8-K
Filed August 24, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 78/100
What the filing says
BioXcel Therapeutics amended its April 2022 Credit Agreement with Oaktree Fund Administration (administrative agent) and lenders. The amendment requires the company to enter definitive agreements for either: (A) full cash repayment of all loan obligations by August 28, 2026, or (B) an alternative capital solutions transaction acceptable to Majority Lenders. The company must also cooperate in good faith with lenders regarding regulatory processes affecting material assets through that same date.
Why this rating
Covenant adds existential deadline for distressed biotech with $11M market cap. Mandatory transaction within 20 months or default risk is material relative to company size.
Tradability signal
SHORT
conviction 31/100 · expected -0.80% over 4 hrs
SHORT (drift): bad news keeps sliding after dissemination — our one persistent measured edge. Similar past filings (13 in this cell) moved +2.34% in the called direction over 4 hrs; shrunk for sample size that's a +0.80% edge. Caution: sub-$5 shorts can be hard to borrow — treat as avoid-longs if no locate.
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it negative)
at our read · backfill $0.84 | +10 min · backfill $0.81 ▼ 3.64% | +30 min · backfill $0.81 ▼ 4.21% | +1 hr · backfill $0.81 ▼ 3.64% | +4 hrs · backfill $0.82 ▼ 2.02% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from August 24, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.